- Home
- NPT vs LONA Comparison
NPT vs LONA Comparison
Compare NPT & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | LONA |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 71.2M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NPT | LONA |
|---|---|---|
| Price | $2.80 | $6.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 14.6K | ★ 40.2K |
| Earning Date | 05-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $4.21 |
| 52 Week High | $22.38 | $14.21 |
Technical Indicators
Market Signals| Indicator | NPT | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 44.48 |
| Support Level | $2.31 | $6.86 |
| Resistance Level | $3.21 | $8.57 |
| Average True Range (ATR) | 0.22 | 0.58 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 11.90 | 29.70 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.